Impact of hyperthyroidism on cardiac hypertrophy

Author(s)

Barreto-Chaves, M. L. M. ; Senger, N. ; Fevereiro, M. R. ; Parletta, A. C. ; Takano, A. P. C.

• Document type: Journal article
• Source: ENDOCRINE CONNECTIONS; v. 9, n. 3, p. 11-pg., 2020-03-01.

Abstract

The cardiac growth process (hypertrophy) is a crucial phenomenon conserved across a wide array of species and is critically involved in the maintenance of cardiac homeostasis. This process enables an organism to adapt to changes in systemic demand and occurs due to a plethora of responses, depending on the type of signal or stimuli received. The growth of cardiac muscle cells in response to environmental conditions depends on the type, strength and duration of stimuli, and results in adaptive physiological responses or non-adaptive pathological responses. Thyroid hormones (TH) have a direct effect on the heart and induce a cardiac hypertrophy phenotype, which may evolve to heart failure. In this review, we summarize the literature on TH function in the heart by presenting results from experimental studies. We discuss the mechanistic aspects of TH associated with cardiac myocyte hypertrophy, increased cardiac myocyte contractility and electrical remodeling, as well as the associated signaling pathways. In addition to classical crosstalk with the sympathetic nervous system (SNS), emerging work pointing to the new endocrine interaction between TH and the renin-angiotensin system (RAS) is also explored. Given the inflammatory potential of the angiotensin II peptide, this new interaction may open the door for new therapeutic approaches which target the key mechanisms responsible for TH-induced cardiac hypertrophy. (AU)

• FAPESP's process: 16/13896-0 - AT1R internalization and Ras/Raf/MEK/ERK signaling in the cardiomyocyte hypertrophy induced by thyroid hormone. role of beta-arrestins
• Grantee: Maria Luiza de Morais Barreto de Chaves
• Support Opportunities: Regular Research Grants